Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06778408 · ClinicalTrials.gov registry record · Phase 2
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
A Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy, sponsored by University of Vermont Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT06778408: Recruiting Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy, sponsored by University of Vermont Medical Center.
NCT06778408 is a Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy that is actively recruiting participants, run by University of Vermont Medical Center. The registered enrollment target is 103 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06778408, a Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy, is actively recruiting participants, sponsored by University of Vermont Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.
Primary Outcome
Th incidence of acute gastrointestinal (GI) toxicity (defined as a score of ≥2) at 4 weeks post-treatment initiation will be measured and compared to historical data, using PRO-CTCAE GI scores to determine if HART reduces GI toxicity.
Conditions Studied
Interventions
- RADIATION Hybrid Palliative Radiation Therapy
Study Locations (1)
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What NCT06778408 shows while recruiting
NCT06778408 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Metastatic Cancer (Different Solid Tumour Types) appearing as the primary indexed condition, and to 1 intervention - of which Hybrid Palliative Radiation Therapy is the first listed.
NCT06778408 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT06778408 about?
NCT06778408 is a clinical study titled "Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial". This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes...
What is the current status of trial NCT06778408?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2025-04-28. Estimated completion is 2028-03.
What conditions does trial NCT06778408 study?
This clinical trial studies the following conditions: Metastatic Cancer (Different Solid Tumour Types), Palliative Radiotherapy.
What interventions are being tested in trial NCT06778408?
The interventions under investigation include: Hybrid Palliative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06778408?
This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06778408 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer (Different Solid Tumour Types)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06778408's enrollment target sits among peer trials
103 664th of 2000 higher than 1,334 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI